Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study by Yuliya Lytvyn, PhD, Asfandyar Mufti, MD, Hiba Zaaroura, MD, Muskaan Sachdeva, BHSc, Justin D. Lu, MSc, Brian D. Rankin, PhD, Vimal H. Prajapati, MD, Ronald Vender, MD, Jensen Yeung, MD, FRCPC

Get full text